Metformin Treatment on Cognitive Impairment of Schizophrenia
Status:
Not yet recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
In this study, the investigators will investigate the effect and the underlying mechanism of
metformin treatment on cognitive impairment in individuals with schizophrenia. The study will
recruit 120 individuals with schizophrenia at 4 sites, who will be randomized to metformin or
placebo group for 24-week treatment. Clinical assessments will be done at screen/baseline,
12th week and 24th week. The specific aims are to compare metformin group versus controls on:
1) cognition; 2) clinical core symptoms. Biological samples also will be collected and stored
to explore related mechanisms.
Phase:
Phase 3
Details
Lead Sponsor:
Central South University
Collaborators:
NINGBO KANGNING HOSPITAL NO.2 PEOPLE'S HOSPITAL OF DALI PREFECTURE Shandong Mental Health Center